Every tumor matters in curing cancer. Vysioneer’s mission is to help cancer patients receive the right treatment at the right moment.
90% of oncology drugs take years and $1B+ but fail miserably in clinical trials.
Vysioneer’s AI unlocks lesion-level drug efficacy, helping pharma de-risk clinical trials, accelerate clinical trials, and reduce costs.
Unlike conventional approaches which uses patient-level data (e.g., ORR) to evaluate treatment efficacy, VBrain revealed longitudinal lesion-level outcome data of brain metastases treated with osimertinib (Tagrisso) at Stanford Cancer Center.
This study provides granular insights into risk of local recurrence in brain to better inform close follow-up and consideration for additional treatment.
Learn more about how Stanford University used VBrain to identify high-risk lesions to guide optimal management.